Month: June 2023

Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...

Applied UV’s Subsidiary, LED Supply Co., and Its FORTUNE® 500 Technology Partner Awarded Approximately $0.8 million Contract for Comprehensive Lighting & Building Controls Solution for Global Auto Manufacturer’s U.S. Facility

Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension

With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...

Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and...

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Breakthrough Solution for Fragile Skin: Covalon’s IV Clear® Dressing Recommended by Physicians at a Top 10 U.S. Children’s Hospital and Epidermolysis Bullosa Center of Excellence

Anesthesiologists recommend Covalon’s gentle and effective silicone solution over acrylic dressings for securing vascular insertion sites in Epidermolysis Bullosa patients...

error: Content is protected !!